Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review

Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. To evaluate the efficacy and safety of rituximab for MS treatment. Studies were selected if they were clinical trials, irrespective of the dosage...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2013-07, Vol.8 (7), p.e66308-e66308
Hauptverfasser:	Castillo-Trivino, Tamara, Braithwaite, Dejana, Bacchetti, Peter, Waubant, Emmanuelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal, Murine-Derived - therapeutic use Arthritis Brain CD20 antigen Central Nervous System - drug effects Central Nervous System - immunology Central Nervous System - pathology Clinical trials Clinical Trials as Topic Complications and side effects Data collection Databases, Bibliographic Drug therapy Epidemiology Gadolinium Humans Immunologic Factors - therapeutic use Immunotherapy Interferon Lesions Lymphocytes Lymphoma Magnetic resonance imaging Mathematics Medical research Medicine Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Chronic Progressive - immunology Multiple Sclerosis, Chronic Progressive - pathology Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - pathology Neurology Pathogenesis Patients Quality Rheumatoid arthritis Rituximab Studies Systematic review Targeted cancer therapy Therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!